
5 Things to Know About Restless Leg Syndrome
1. Up to 10% of the U.S. population may suffer from RLS Onset can happen at any stage of life, affecting both genders, although females are more prone to it.
Neuropathy is very common, and it’s estimated that at least 8% of the world's population has it. The United States alone has over 40 million people suffering from neuropathy, and their associated health costs exceed $4 billion annually. Presently, over 50% of diabetics, 20% of cancer patients undergoing chemotherapy and at least 10% of the US population 40 years and older will be diagnosed with neuropathy.
We are working to prevent and reverse nerve damage associated with peripheral neuropathy through the repair and regrowth of peripheral nerves. Our results validate the discovery of a pathway to regenerate peripheral nerves and reduce symptoms associated with peripheral nerve damage.
Who We Are:
+ Key Opinion Leaders
+ Leading Institutional Stakeholders
+ Proven Management Team
+ World Class Advisors
We have one mission—impact patients’ lives. We follow the science to lead us to this goal. Currently, we are focused on managing global resources to accelerate the development of potentially disease-modifying treatments for patients with peripheral neuropathy.
1. Up to 10% of the U.S. population may suffer from RLS Onset can happen at any stage of life, affecting both genders, although females are more prone to it.
The importance of understanding inflammation in pain resolution Inflammation is more than a
WinSanTor Inc. is a private biotechnology company focused on the discovery and development of treatments for peripheral neuropathies. WinSanTor recently completed Phase 1 trials for its lead drug, WST-057, and will begin recruiting for its Phase 2 trials in Canada to treat patients with diabetic peripheral neuropathy.
Cookie | Duration | Description |
---|---|---|
cookielawinfo-checkbox-analytics | 11 months | This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Analytics". |
cookielawinfo-checkbox-functional | 11 months | The cookie is set by GDPR cookie consent to record the user consent for the cookies in the category "Functional". |
cookielawinfo-checkbox-necessary | 11 months | This cookie is set by GDPR Cookie Consent plugin. The cookies is used to store the user consent for the cookies in the category "Necessary". |
cookielawinfo-checkbox-others | 11 months | This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Other. |
cookielawinfo-checkbox-performance | 11 months | This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Performance". |
viewed_cookie_policy | 11 months | The cookie is set by the GDPR Cookie Consent plugin and is used to store whether or not user has consented to the use of cookies. It does not store any personal data. |